Little is known about outcomes of acute myeloid leukemia (AML) in adolescents and young adults (AYA), a unique subgroup of AML patients. We retrospectively analyzed all AML patients (n [ 3922) aged 16 to 29 years, treated at our institution from 1965 to 2009 and found 432 (11%) AYA AML. Over time, outcomes for AYA AML patients have improved compared with older adults with AML. Background: Little is known about outcomes of acute myeloid leukemia (AML) in adolescents and young adults (AYA). The purpose of this study is to determine the characteristics and outcomes of AYA AML patients in comparison to older adult patients with AML. Patients and Methods: We retrospectively analyzed all AML patients treated at our institution from 1965 to 2009 who were aged 16 to 29 years. Results: Among 3922 adult AML patients treated during this period, 432 (11%) were identified as AYA. Median age was 23 years (range, 16-29 years); 73 (17%) patients had core binding factor (CBF)-AML [inversion (16), translocation (8:21)], and 51 (12%) had acute promyelocytic leukemia. Complete remission (CR) rates were 93% for CBF AML, 78% for APL, 77% with diploid karyotype, and 68% for other AML. Univariate analysis demonstrated higher rates of CR, CR duration, and overall survival (OS) in the AYA group compared with older patients. On multivariate analysis, AYA age group was independently associated with improved CR rate and CR duration, with a trend for longer OS (P ¼ .085). Conclusion: Outcome of AYA AML patients is overall better than for older adults with AML. Despite improvements in treatments and outcomes over time, there is still need for improvement in AYA with AML particularly for those with AML other than CBF and APL.
Introduction
Acute myeloid leukemia (AML) is typically a disease of older adults with an age-adjusted incidence of 3 to 4:100,000 in Western countries, with a median age at the time of diagnosis of 70 years. 1 AML accounts for approximately one-third of all leukemia cases in the United States, with estimated incidence of 18,860 newly diagnosed patients and 10,460 patient deaths in the United States in 2014. 2 Age at the time of diagnosis is one of the most important prognostic features, with the prognosis worsening with increasing age, even when accounting for cytogenetic risk groups. 3 The impact of age has focused mostly on the older age groups, which has suggested that outcomes have consistently been more unfavorable in patients older than ages 60 to 65 years. 4 Some of these differences are related to patient characteristics (eg, worse performance status among older patients, more comorbidities, poor tolerance for intensive chemotherapy) and others due to disease biology (eg, an increased incidence of high-risk chromosomal abnormalities and higher frequency of multi-drug resistance expression).
striking lack of progress in treatments and outcomes compared with both younger pediatric and older patient populations. 6, 7 AYA with leukemia are a unique group of cancer patients that may exhibit distinctive patient and disease characteristics compared with other age groups and other cancer patients. [8] [9] [10] Much has been reported about the prognosis of AYA with acute lymphoblastic leukemia (ALL). 11, 12 Among patients with ALL, analysis of the Surveillance, Epidemiology, and End Results (SEER) database has shown a significant improvement in overall survival (OS) for adolescents, young adults, and older adults over the past 2 decades, with a significant OS improvement in AYA (ages 15-19) whose 5-year relative survival improved from 41% to 62%. 11, 13, 14 Outcomes in patients focusing on pediatric AML have been reviewed by various groups, and demonstrate significant improvements over time. [15] [16] [17] Little is known, however, about the outcomes of the specific subset of the AYA AML group, treated with adultaimed chemotherapy. This study investigates the characteristics and outcomes of AML in AYA at our institution and compares outcomes with those of older patients on the same chemotherapy regimens.
Patients and Methods
Patients with AML treated in the Department of Leukemia at MD Anderson Cancer Center (MDACC) from 1965 to 2009 were analyzed. Patients aged 16 to 29 years were defined as AYA and are the focus of this analysis. Among the 3922 adult AML patients seen during this period, 432 (11%) were AYA, and were included in our analysis. Patient, disease, and treatment characteristics were analyzed, including: age at diagnosis, cytogenetics at time of diagnosis, history of antecedent hematologic disease (AHD), primary versus secondary (including treatment-related) AML, other disease characteristics, and treatment administered. When available, molecular testing for FLT3 mutations was also included. Only patients receiving their induction therapy at our institution were considered for this analysis. All patients were treated under protocols approved by the Institutional Review Board, and all patients signed informed consent in accordance with rules and regulations of the Declaration of Helsinki. The study was approved in a separate protocol approved by the Institutional Review Board.
To compare outcomes over time, patients were grouped into 3 treatment eras: 1965 to 1984, 1985 to 2000, and 2001 to 2009. When divided by treatment era, AYA patients represented 41%, 26%, and 19%, respectively, of AML patients treated.
Response Criteria
Responses were defined as per the International Working Group criteria. 18 For each treatment era and cytogenetic group, we investigated induction mortality, complete remission (CR) rate, and CR duration, and compared these values over time.
Statistical Methods
Kaplan-Meier curves were generated for assessment of OS with comparison of groups performed by log-rank testing. Fisher exact test or Mann-Whitney U test was employed for comparisons of non-parametric data with categorical or continuous variables, respectively. The t-test was performed to analyze differences among subgroups by covariates for parametric data. Generalized linear modeling was used to determine potential predictive factors for CR. The statistical analysis was performed using STATA/SE version 13.1 statistical software (Stata Corporation, LP, College Station, TX). Both univariate (via log-rank testing) and multivariate analysis (via Hazard Cox Regression modeling with extraction of significant variables from the univariate testing) were performed. For this analysis, P-values < .05 were considered statistically significant for univariate analysis; P-values < .10 on univariate analysis were included in multivariate logistic regression modeling to assess for independent determinants of CR, CR duration, and OS.
Results
Patient characteristics are summarized in Table 1 . The median age of the 432 AYA patients was 23 years (range, 16-29 years). These included 73 (17%) patients with core binding factor (CBF) and 51 (12%) patients with acute promyelocytic leukemia (APL). In addition, 97 (22%) patients had diploid cytogenetics, and 19 patients (4%) had monosomy 5 (À5) and/or monosomy 7 (À7) with complex cytogenetics. Miscellaneous cytogenetic abnormalities were identified in 167 patients (39%): 47 patients (11%) with other non-complex cytogenetics ( 3 abnormalities), 29 (7%) with other complex cytogenetics (! 3 abnormalities), 12 (3%) with insufficient metaphases, and cytogenetics unknown or unavailable in 101 patients (23%). AHD, defined as documented abnormalities in peripheral blood counts prior to the diagnosis of AML, were present in 74 patients (17%). A prior malignancy had been diagnosed in 26 patients (6%), and 21 (81%) had received chemotherapy for their prior malignancies. The most common prior tumors were sarcoma (n ¼ 6) and lymphoma (n ¼ 6; 4 Hodgkin's lymphoma). Four patients had prior hematologic malignancies: 3 myelodysplastic syndrome (MDS) and 1 prior aplastic anemia.
Seventy-eight AYA patients were evaluated for FLT3, with mutations identified in 28%: 17 (22%) patients had internal tandem duplication, 19 8 (10%) had D835 point mutation, and 3 (4%) had both FLT3-ITD and D835 abnormalities. An NPM1 mutation was identified in 6 of 23 evaluable patients (26%).
Response to Treatment
CR was achieved in 329 (76%) patients (including 2 with CR with incomplete recovery of platelets). The CR rates were 68/73 (93%) for CBF AYA AML, 40/51 (78%) for AYA APL (7/8 [88%] for AYA APL treated with all-trans retinoic acid [ATRA] plus arsenic as frontline therapy), and 77/97 (78%) for AYA patients with diploid cytogenetics.
Since the focus of this analysis was on younger AML patients, for reference we also classified the patients according to the revised Medical Research Council (MRC) criteria. 20 The CR (40%) died in CR1, 3 relapsed, and 10 (45%) are still alive and in CR at a median of 80 months (range, 6 months-25 years). The median remission duration for the total population was 16 months, with 31% of patients maintaining CR1 after 5 years. This includes 307 treated with chemotherapy only and 22 patients who received a SCT in CR1. The median CR duration was not reached for those receiving SCT and 14 months for those without SCT. We then compared OS among the 123 AYA patients who underwent SCT versus the 309 patients who did not undergo SCT; there was a statistically significant difference found favoring those who went to SCT (P ¼ .04). However, the 5-year OS rate was identical (28% for both groups).
The 5-year survival probability for all AYA patients was 28%, and the 5-year probability of sustained remission was 31%. Long-term outcomes were better for patients with CBF-AML (5-year survival, 49%; probability of sustained CR, 43%) and APL (5-year survival, 47%; sustained CR, 50%) compared with diploid (5-year survival, 32%; probability of sustained CR, 29%) and other AML (5-year survival, 16%; sustained CR, 21%; P < .001; Figure 1A ,B). OS among AYA patients improved significantly over time, with 5-year survival rates of 15%, 35%, and 53%, respectively, for the 3 time periods analyzed (P < .001). Similarly, the 5-year CR duration was 20%, 32% and 52%, respectively (Figure 2A ,B).
Supplemental Table 1 (OS 5-year) and Supplemental Table 2 (CR duration 5-year) of the Supplemental section (see Supplemental Tables 1 and 2 in the online version) contain data on distribution by cytogenetic group by era.
We then analyzed the outcome over time by cytogenetic group. Significant improvement in OS was observed among patients with CBF (P ¼ .028) and APL (P ¼ .033) but not among those with diploid cytogenetics (P ¼ .121). There was a similarly notable but not statistically significant trend for improvement in CR duration over time for the CBF and APL groups (P ¼ .055 and P ¼ .214, respectively; Figures 3A,B, 4A ,B, and 5A,B). No discernible improvement was seen for the diploid group.
Among the 17 AYA patients with FLT3-ITD mutation, one had APL. Among the 16 remaining non-APL patients with FLT3-ITD mutation, 11 (69%) achieved CR. One patient is alive and in remission (after SCT and in CR1) after 5 years; the other 9 relapsed and 7 died, 4 after SCT. 
Comparative Analysis With Older Patients
We then analyzed the AYA patient characteristics and outcome compared with those of patients of other age groups treated in the same time period (Table 1) . AYA patients were more likely to have higher white blood cell (WBC) count, higher bone marrow and peripheral blood blast percent, higher hemoglobin levels at baseline, more likely to have CBF AML and APL, more likely to have received SCT in first CR, and more commonly diagnosed in 2001 to 2009. CR for patients aged 16 to 29 years was 76%, with 5-year survival of 33%; for ages 30 to 59 years, CR was 74% and 5-year survival 31%; for ages 60 to 65 years, CR was 64% with 5-year survival 16%, and for patients aged greater than 65 years, CR was 56% with 5-year survival of 10%.
Predictors of Outcome
To define whether AYA age group was independently associated with outcome, we analyzed the characteristics associated with outcome compared with older patients. For this purpose, we included 3918 (99.8%) of the 3922 patients evaluated within 4 weeks of diagnosis (4 patients had occurrence of 2 separate AML diagnoses during their treatment history, and were counted only once for comparative analysis).
In univariate analysis for CR, CR duration, and OS, AYA patients had significantly greater rates of all 3 outcome measures compared with older patients. Specifically, for the AYA group, there was an increased CR rate (76% vs. 58% for older patients; odds ratio [ Other factors associated with improved CR rate were a trend towards improved CR rate with ATRA-based chemotherapy (for APL patients, but not statistically significant) and no prior chemotherapy/radiation; factors associated with inferior CR rate were prior AHD and other non-complex cytogenetics. Other factors associated with longer CR duration were treatment with ATRA-based therapy (APL patients), and factors associated with shorter CR duration were trend towards other non-complex cytogenetics (P ¼ .092). For OS, the multivariate analysis identified the following factors to be independently predictive of inferior outcome: unfavorable cytogenetic abnormalities (-5/-7 [HR, 2.42; P < .001] and other complex cytogenetics [HR, 1.37; P ¼ .001]); prior chemotherapy (HR, 1.54; P < .001), FLT3-ITD positivity (HR, 1.75; P < .001), and chemotherapy treatment of HDAC þ no anthracycline AE other agents (HR, 1.36; P ¼ .010), and "other" chemotherapies (HR, 2.25; P < .001), as compared with HDAC þ anthracycline. There was a trend towards improved OS for the AYA group, but this was not statistically significant (HR, 0.74; 95% CI, 0.53-1.04; P ¼ .085). Table 2 contains data for the univariate (Table 2 ) and multivariate (Table 3) analyses for the overall group.
To account for the higher incidence of adverse chromosomal abnormalities in older patients, we then performed a subset analysis of only patients with diploid cytogenetics. Among 1231 patients of all ages who exhibited diploid cytogenetics, 97 (8%) were AYA. In the univariate analysis, CR and OS were significantly better for AYA (n ¼ 97) as compared with the older patients (n ¼ 1134) with diploid cytogenetics, but no significant difference was observed with CR duration. By multivariate analysis, there was a trend in favor of the AYA group for CR (P ¼ .07) and OS (P ¼ .052). Supplemental Tables 3 and 4 (see Supplemental Tables 3 and 4 in the online version) contain the univariate and multivariate analysis for the diploid cytogenetics group.
Discussion
Although AML is typically a disease of older patients, (median age, 65-70 years) it still accounts for 15% to 20% of childhood leukemias 21 and 33% of adolescent leukemias. [22] [23] [24] In this singleinstitution analysis, the outcome of AYA patients with AML was significantly better than that for older adults with AML, with improved CR and CR duration rates, and a trend towards improved OS. There has also been an improvement of outcomes over time for AYA patients with AML, likely the result of a variety of factors including improvements in supportive care, intensity of treatments, and application of specific, targeted therapies to certain subsets of patients (eg, APL). There is growing recognition that AYA patients with cancer may represent a unique cohort with special needs. 25 This "in-between" age group has age-specific pharmacological, 26 toxicity profile, 27 psychosocial, 28 adherence, 29 fertility, 30 socio-economic, 31 access to and the cost of healthcare, 32 and palliative care needs 33 that may set it apart from other age groups of patients dealing with cancer. In leukemias, more is known about the incidence and outcomes in 
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AYAs with ALL, as this malignancy occurs more frequently in younger age groups than its myeloid counterparts. 9, 34 Notably, for both solid and hematologic cancer patients, the AYA population has been underrepresented in clinical trials. 35, 36 Access to and availability of new therapeutic options can also be improved for these young patients. In response to the growing awareness of AYA oncology patients, the National Comprehensive Cancer Network (NCCN) has recently published AYA oncology guidelines. 37 The age range that defines AYA has varied; the NCCN has set age range for its current guidelines to include ages 15 to 39 years as AYA, but others have used other age ranges, including 15 to 29 years. 38, 39 In this analysis, we focused on patients aged 16 to 29 years as this age group has been used extensively in the AYA literature. 34, 38 The effect of age on outcome of patients with AML has been extensively studied, but most analyses have focused on the older age groups. Appelbaum and colleagues analyzed 968 adults with AML and demonstrated that outcomes were significantly worse for older versus younger patients, arguing for age-specific assessments in the therapeutic evaluation of AML patients. 3 The recently proposed cytogenetic classification for younger patients with AML includes patients younger than 60 years. 20 Some population series have analyzed the outcome of AYA patients with AML. Based on analysis of the SEER database, Pulte and colleagues demonstrated increasing relative survival rates in younger AML patients and continued improved expected survival rates in this younger population. 40 demonstrated an improved survival among almost every age group over time. The progressive increase in outcomes was attributed to a variety of factors including more intensified chemotherapy, improvement in supportive care and transfusions, and improvements in allogeneic SCT. Still, the authors remarked that, although AML survival has improved over time for all age groups, the The outcome of AYA patients (ages 16-24 years) in the AML10 and AML 12 trials conducted by the MRC showed 10-year OS of 47%, relapse rate of 47%, 14% deaths in CR, with 61% patients considered good-risk. 12 In a Japanese study of greater than 1000 patients with AML aged 1 to 29 years, the 7-year event-free survival was 32% among patients aged 15 to 19 years. 41, 42 Similar results were found by other groups, again concluding that even among young patients, increasing age still confers an unfavorable prognostic factor in AML patients. 22, 38, 43 Among all age groups, there are many factors that have led to the improvement in outcome of AML patients, including better supportive care, the availability of clinical trials, and the incorporation of targeted therapies, especially for many high-risk sub-groups. 44, 45 The reasons in particular for some of the improved outcomes among AYA patients with AML as compared with their older counterparts over time likely includes a multifactorial explanation, encompassing both patient/host and AML disease biology. In terms of host biology, some of these factors include the overall likelihood of the AYA patient to better tolerate AML chemotherapy and for AYA patients to be better suited for more dose-intense regimens. Other host factors include that most AYA patients have less comorbid conditions at baseline and are taking less concomitant medications (therefore resulting in less drug-drug interactions and toxicities) as compared with their older counterparts. In terms of disease biology, AYA patients tend to have lower incidence of abnormal/complex cytogenetics and reduced occurrence of secondary/therapy-related AML as compared with older AML patients. In our study, among patients treated in an adult setting with adult-type chemotherapy, we demonstrate significantly better outcomes of AYA patients over time, with CR duration reaching 81% and OS 53% in the most recent decade analyzed. In our series, the most important improvements occurred in the CBF and APL groups, where 5-year survival rates are 49% and 47%, respectively. Patients with diploid cytogenetics lag behind significantly with a rate of only 32%, and even worse for those with adverse/other cytogenetic features, with a rate of only 16%; one possible explanation for this observation includes the recent elucidation of poor prognostic molecular mutations (eg, FLT3-ITD, DNMT3a) that transform an intermediate-risk patient to high/poor risk status. Clearly better therapies, including targeted therapies aimed at particular molecular mutations, are needed in AYA patients with these features.
On multivariate analysis modeling, the AYA age group was significantly associated with increased CR rate and CR duration, and a trend towards survival improvement (P ¼ .085).
One limitation of the current study is the lack of molecular data on all patients analyzed, due to the historical nature of our analysis, when molecular abnormalities well-recognized today had not yet been identified. Several studies have demonstrated that the poorer prognosis in FLT3-ITD AML is sustained even in 50 our analysis focused on cytogenetic subgrouping, as this was available on the majority of patients included in the study period. Future studies will further define the impact of molecular characterization in the AYA population.
In conclusion, patients with AYA constitute a unique subset of patients with AML with an improved prognosis compared with other age groups. However, despite the notable improvements in outcomes over time, there is still significant need for improvement in this patient population, including greater emphasis on availability, access to, and enrollment in clinical trials.
Clinical Practice Points
AYA with cancer represent a potentially vulnerable subgroup of patients with unique features and diverse needs Little is known about characteristics and outcomes of AYA patients with leukemia outside of the field of ALL, particularly for AYA AML patients On multivariate analysis, AYA AML age group was independently associated with improved CR rate and CR duration, with a trend for longer OS (P ¼ .085) Outcomes for AYA AML patients have improved over time, as compared with older adults with AML. Despite improvements in treatments and outcomes over time, there is still need for improvement in AYA with AML particularly for those with AML other than CBF AML and APL Supplemental 
